Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol’s admilparant — though it’s unclear whether the drug was to blame.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.